Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured an undisclosed amount of funding in a Series D+ financing round. The round was led by existing investor Sherpa Healthcare Partners, with additional contributions from Taiping Fund Management, Triwise Capital, and Far East Horizon, as well as returning investor Sequoia Capital China. The proceeds will be directed towards market promotion, manufacturing capacity expansion, and research and development (R&D) of the company’s product pipeline.
Company Highlights and Product Approvals
Insight Lifetech is recognized for its pioneering achievements in cardiovascular technology. The company’s fractional flow reserve (FFR) system is the first and only domestic FFR system approved by the National Medical Products Administration (NMPA) in China, having also obtained the CE Mark in March 2020. Additionally, its in-house developed 1st Generation Intravascular Ultrasound (IVUS) system was the first domestic IVUS system to enter clinical trials and complete patient enrollment in China. With Category III device approval in China, the IVUS system is now poised for widespread adoption in hospitals nationwide.
Future Outlook
With the support of this latest financing round, Insight Lifetech is well-positioned to enhance its market presence and drive innovation in cardiovascular interventions. The funding will enable the company to expand its manufacturing capabilities, accelerate product development, and further promote its solutions in the global market.-Fineline Info & Tech
